These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
    Author: Grigor'ev PIa, Iakovenko EP, Talanova EV.
    Journal: Klin Med (Mosk); 2001; 79(6):41-4. PubMed ID: 11521379.
    Abstract:
    Epidemiological and clinical findings suggest that the spread of Helicobacter pylori (H.p.) infection as an etiological and pathogenetic agent is of prime importance for patients with pelvic ulcer and chronic gastritis. However, there are relatively scanty papers on the impact of therapy against H.p. on its eradication rate, symptom arrest, and the course of diseases. A great deal of drug combinations have been proposed to eradicate H.p. infection and some of them are even classical (omeprazole in combination with 2-3 antibiotics). The H.p. eradication with this combination for 7 days is as high as 85-90%. These regimens are recommended for practical application in Europe and Russia. The authors' studies in 90 patients (34 with duodenal ulcers, 34 with gastric ulcers, and 28 with chronic duodenitis) indicate that lansofed used in 7-day combined therapy is highly effective in suppressing acid production, abolishing symptoms during an exacerbation of peptic ulcer (gastroduodenitis) and in eradicating H.p. infection. There is evidence for that the use of the agent in combination with 2 and 3 anti-H.p. drugs rapidly arrest the symptoms of a disease, frequently diminishes an inflammatory process and lead to a remission.
    [Abstract] [Full Text] [Related] [New Search]